Item Details

19 Nov 2026

VitriVax raises $87 million to develop next generation vaccines

US biotechnology company VitriVax announced an oversubscribed $87 million Series C funding round on 18 November. The investment will support the development of its Lyme disease vaccine and expansion of its wider vaccine pipeline. Investors include F Prime, NEA, RA Capital Management, Sanofi Ventures and Eli Lilly. HPC could connect biotechnology startups with pharmaceutical investors, research partners and specialist manufacturing companies.

Get in Touch

We’ll get back to you shortly.